Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 5, 2008, Pages 875-880

  Ku, Geoffrey Y ^a   Ilson, David H ^a   Schwartz, Lawrence H ^a   Capanu, Marinela ^a   O'Reilly, Eileen ^a   Shah, Manish A ^a   Kelsen, David P ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bryostatin 1; Esophageal cancer; Gastroesophageal cancer; Paclitaxel; Protein kinase C

Indexed keywords

BRYOSTATIN 1; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; LUNG TOXICITY; MALE; MORTALITY; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEQUENTIAL INJECTION ANALYSIS; STOMATITIS; THROMBOSIS; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 49749093093     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0677-y     Document Type: Article

References (27)

1. JA Ajani Y Jiang J Faust BB Chang L Ho JC Yao S Rousey S Dakhil RC Cherny C Craig A Bleyer 2006 A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma Invest New Drugs 24 353 357
2. C Asiedu J Biggs M Lilly AS Kraft 1995 Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2 Cancer Res 55 3716 3720
3. PC Enzinger RJ Mayer 2003 Esophageal cancer N Engl J Med 349 2241 2252
4. DL Evans C Dive 1993 Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes Cancer Res 53 2133 2139
5. S Grant WD Jarvis PS Swerdlow AJ Turner RS Traylor HJ Wallace PS Lin GR Pettit DA Gewirtz 1992 Potentiation of the activity of 1-beta-D- arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA Cancer Res 52 6270 6278
6. A Haimovitz-Friedman CC Kan D Ehleiter RS Persaud M McLoughlin Z Fuks RN Kolesnick 1994 Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis J Exp Med 180 525 535
7. H Hennings PM Blumberg GR Pettit CL Herald R Shores SH Yuspa 1987 Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin Carcinogenesis 8 1343 1346
8. PF Hickman GJ Kemp CH Thompson AJ Salisbury K Wade AL Harris GK Radda 1995 Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study Br J Cancer 72 998 1003
9. DH Ilson RG Wadleigh LP Leichman DP Kelsen 2007 Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer Ann Oncol 18 898 902
10. WD Jarvis FA Fornari Jr. JL Browning DA Gewirtz RN Kolesnick S Grant 1994 Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells J Biol Chem 269 31685 31692
11. WD Jarvis RN Kolesnick FA Fornari RS Traylor DA Gewirtz S Grant 1994 Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway Proc Natl Acad Sci USA 91 73 77
12. A Kaubisch D Kelsen L Saltz N Kemeny E O'Reilly D Ilson S Endres J Barazzuol G Schwartz 1999 A pase I trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumors Proc Amer Soc Clin Onc 18 166a (Abstract 639)
13. JA Koutcher M Motwani KL Zakian XK Li C Matei JP Dyke D Ballon HH Yoo GK Schwartz 2000 The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow Clin Cancer Res 6 1498 1507
14. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214
15. RM Mohammad A al-Katib GR Pettit LL Sensenbrenner 1994 Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents Cancer Res 54 165 168
16. National Cancer Institute (1999) NCI, Common Toxicity Criteria, version 2.0,. Bethesda
17. LM Obeid CM Linardic LA Karolak YA Hannun 1993 Programmed cell death induced by ceramide Science 259 1769 1771
18. PA Philip AL Harris 1995 Potential for protein kinase C inhibitors in cancer therapy Cancer Treat Res 78 3 27
19. PA Philip D Rea P Thavasu J Carmichael NS Stuart H Rockett DC Talbot T Ganesan GR Pettit F Balkwill 1993 Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee J Natl Cancer Inst 85 1812 1818
20. GK Schwartz MA Shah 2005 Targeting the cell cycle: a new approach to cancer therapy J Clin Oncol 23 9408 9421
21. LH Schwartz JA Colville MS Ginsberg L Wang M Mazumdar J Kalaigian H Hricak D Ilson GK Schwartz 2006 Measuring tumor response and shape change on CT: esophageal cancer as a paradigm Ann Oncol 17 1018 1023
22. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10
23. CH Thompson VM Macaulay KJ O'Byrne GJ Kemp SM Wilner DC Talbot AL Harris GK Radda 1996 Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply Br J Cancer 73 1161 1165
24. PA Wender MO Clarke JC Horan 2005 Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs Org Lett 7 1995 1998
25. PA Wender JC Horan 2006 Synthesis and PKC binding of a new class of a-ring diversifiable bryostatin analogues utilizing a double asymmetric hydrogenation and cross-coupling strategy Org Lett 8 4581 4584
26. PA Wender JC Horan VA Verma 2006 Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs Org Lett 8 5299 5302
27. PA Wender VA Verma 2006 Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin Org Lett 8 1893 1896